Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CNTA
Upturn stock ratingUpturn stock rating

Centessa Pharmaceuticals PLC ADR (CNTA)

Upturn stock ratingUpturn stock rating
$14.03
Last Close (24-hour delay)
Profit since last BUY-0.28%
upturn advisory
Strong Buy
BUY since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/09/2025: CNTA (5-star) is a STRONG-BUY. BUY since 4 days. Profits (-0.28%). Updated daily EoD!

Upturn Star Rating

rating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Number of Analysts

rating

11 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $31.5

1 Year Target Price $31.5

Analysts Price Target For last 52 week
$31.5 Target price
52w Low $9
Current$14.03
52w High $19.09

Analysis of Past Performance

Type Stock
Historic Profit 108.37%
Avg. Invested days 40
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/09/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.81B USD
Price to earnings Ratio -
1Y Target Price 31.5
Price to earnings Ratio -
1Y Target Price 31.5
Volume (30-day avg) 11
Beta 1.49
52 Weeks Range 9.00 - 19.09
Updated Date 07/9/2025
52 Weeks Range 9.00 - 19.09
Updated Date 07/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.88

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -205.18%

Management Effectiveness

Return on Assets (TTM) -28.58%
Return on Equity (TTM) -74.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1645361575
Price to Sales(TTM) 120.79
Enterprise Value 1645361575
Price to Sales(TTM) 120.79
Enterprise Value to Revenue 109.69
Enterprise Value to EBITDA 1.12
Shares Outstanding 133619000
Shares Floating 85935578
Shares Outstanding 133619000
Shares Floating 85935578
Percent Insiders 0.5
Percent Institutions 94.42

ai summary icon Upturn AI SWOT

Centessa Pharmaceuticals PLC ADR

stock logo

Company Overview

overview logo History and Background

Centessa Pharmaceuticals PLC ADR (CNTX) was formed in 2021 through the combination of 10 private drug discovery and development companies. The company focuses on discovering and developing innovative therapies for patients with high unmet medical needs.

business area logo Core Business Areas

  • Oncology: Development of therapies for various cancer types.
  • Hematology: Development of treatments for blood disorders.
  • Immunology: Development of therapies to modulate the immune system.
  • Neuroscience: Development of treatments for neurological disorders.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is based on functional areas, including research and development, clinical development, and commercial operations. CEO is Saurabh Saha.

Top Products and Market Share

overview logo Key Offerings

  • CTX-009: CTX-009 is a PD-L1 ADC for the treatment of solid tumors. Phase 1/2 trials are ongoing. Competitors include multiple companies developing ADCs such as Seagen (SGEN), ImmunoGen (IMGN).
  • CTX-211: CTX-211 is a anti-C4b monoclonal antibody to treat paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. Phase 1/2 trials are ongoing. Competitors include Alexion/AstraZeneca (AZN) with Soliris and Ultomiris.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and dynamic, with a focus on innovation and addressing unmet medical needs. Trends include the development of targeted therapies, personalized medicine, and digital health solutions.

Positioning

Centessa is a clinical-stage biopharmaceutical company. Its pipeline is focused on novel drug candidates. Competitive advantages include a diversified pipeline, experienced leadership team, and a focus on high-value therapeutic areas.

Total Addressable Market (TAM)

The TAM for the various therapeutic areas Centessa is addressing is in the billions of USD. Centessa's positioning is focused on innovative approaches to underserved patient populations.

Upturn SWOT Analysis

Strengths

  • Diversified pipeline
  • Experienced leadership team
  • Focus on high-value therapeutic areas
  • Innovative drug candidates

Weaknesses

  • Clinical stage company with no approved products
  • Reliance on clinical trial success
  • High cash burn rate
  • Dependence on financing

Opportunities

  • Successful clinical trial outcomes
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Acquisition of complementary technologies

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • AZN
  • SGEN
  • IMGN

Competitive Landscape

Centessa competes with large, established pharmaceutical companies and smaller biotech companies. Centessa's advantage lies in its innovative pipeline and focus on addressing unmet medical needs. A disadvantage is its need for clinical trial success for revenue generation.

Growth Trajectory and Initiatives

Historical Growth: The company's historical growth is defined by the expansion of its pipeline and clinical trial progress since its formation in 2021.

Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates vary widely depending on the perceived likelihood of success of the pipeline programs.

Recent Initiatives: Recent strategic initiatives include initiating and advancing clinical trials for lead programs, forging partnerships, and expanding the scientific team.

Summary

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company with a diversified pipeline. The company is pre-revenue so is dependent on financing and clinical trial successes. Centessa's innovation is promising but very high-risk. Failure of key clinical trials could harm shareholder returns.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Centessa Pharmaceuticals PLC ADR investor relations website
  • SEC filings
  • Analyst reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor. Market share estimates are based on available data and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Centessa Pharmaceuticals PLC ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-05-28
CEO & Director Dr. Saurabh Saha M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 86
Full time employees 86

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.